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httpcense.Abstract Several guidelines have endorsed inhaled corticosteroids (ICs) as superior for mild per-
sistent asthma. The use of Leukotriene modiﬁers has been showing an effective potential based on
reports in past years. In this study the efﬁcacy of a single daily dose of 200 lg of inhaled ﬂuticasone
propionate was compared with that of the recommended dose of 10 mg of oral montelukast. Com-
parative data were based on the measurement of speciﬁc biomarkers including IgE, eosinophil
count, interleukin 4 (IL-4) and fractional exhaled nitric oxide (FENO) as airway inﬂammation pre-
dictors and routine investigations were determined including the pulmonary function tests and X-
ray imaging. After week 16, the levels of FENO, IgE, Forced expiratory volume in one second
(FEV1) and eosinophilia count percentage were recognized to be of lower signiﬁcance in asthmatic
patients treated with ICS in comparison to those under treatment of leukotriene modiﬁers. Also, the
results revealed a signiﬁcant positive correlation between FENO level and eosinophil count
(r= 0.272, p= 0.047).
The clinical effectiveness of a low dose of ﬂuticasone propionate was superior clinically as a ﬁrst-
line of choice in patients with persistent asthma to that of mentulokast.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
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Asthma prevalence has been escalated greatly during the previ-
ous 30 years [1]. This is more serious in countries with limited
resources and lower public awareness. In Egypt and Middle
East Countries, asthma became a real challenge and a major
public health problem [2].he Egyptian Society of Chest Diseases and Tuberculosis.
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eral guidelines including national institute of health guidelines
have recognized inhaled corticosteroids (ICS) as a leading
medication among other controller medication [3]. Despite
ICS proven efﬁciency in the treatment of mild, moderate,
and severe persistent asthma, it is still under discussion if
should be replaced by other medications including leukotriene
modiﬁers. Leukotriene modiﬁers as new treatment class of
asthma are considered as an alternative to low dose ICS
according to current British and American guidelines [4]. The
leukotriene modiﬁers exist in the local and international mar-
kets and it includes the leukotriene receptor antagonists,
zaﬁrlukast, pranlukast, montelukast, and the 5-lipoxygenase
inhibitor zileuton.
Considering the relative response characteristics, the deci-
sion of whether to use inhaled corticosteroids or leukotriene
modiﬁers as ﬁrst-line controller therapy should be based on
the results of clinical trials that compare the clinical efﬁcacy,
safety, convenience of use and anti-inﬂammatory response [5].
Leukotriene modiﬁers alternatively could be used instead of
an inhaled corticosteroid in patients with mild persistent asth-
ma, according to National Asthma Education and Prevention
Program (NAEPP) guidelines [6]. However, the decision to
choose a leukotriene receptor antagonist (LTRA) in conjunc-
tion with an ICS should be well reported with strong evidence.
Hence the main objective of this study was to evaluate the
anti-inﬂammatory effect and clinical efﬁcacy in patients with
mild persistent asthma of oral leukotriene-modiﬁers and com-
pare it to inhaled corticosteroid.Patients and methods
The ethics committee at Bany Suef University has approved
this study. The study included 60 subjects, where 40 adults
were diagnosed as mild persistent asthma as deﬁned by the
Global Initiative for Asthma (GINA) guideline [3]. They were
divided into three groups; ﬁrst and second groups included the
patients suffering from mild persistent asthma. The ﬁrst group
(n= 20) had received oral montelukast (10 mg once daily) for
16 weeks; the second group (n= 20) had received inhaled cor-
ticosteroid (ﬂuticasone propionate 200 lg) for the same period.
The third group included 20 healthy adults age and sex
matched, serving as a control group. All the selected subjects
were between 22 and 45 years with a history of asthma for
more than 6 months.
The following patients were excluded; patients with
other baseline differential disease (congestive heart failure,
COPD, pulmonary embolism; mechanical obstruction of
airways, and vocal cord dysfunction); patients who had
upper or lower airway infections in the previous 3 weeks;
Any patients on corticosteroids in the last month; patients
with parasitic infestation; Patients who had used in the pre-
vious month or during the study any bronchoconstrictors
e.g. beta-blockers; hypertension or heart related diseases’
patients and pregnant; nursing women and immunocompro-
mised persons.
All subjects were guided to full clinical examination, spi-
rometry, anthropometric measurements and assessment of
fractional exhaled nitric oxid (FENO) level, IgE and eosino-
philic count. Reassessment of these parameters was done to
asthmatic adults after the treatment period.Eligible patients were asked to use short acting
b2-agonist (SABA), salbutamol (Ventolin) inhalation by
MDI with spacer whenever needed during the 4 months
of treatment. Using of SABA is recorded and well noted
during the study.
During each visit (week 1 and 16), the following parameters
were considered:
1. History and clinical examination.
2. The Pulmonary functions, measured three times and the
highest value was considered to deﬁne the efﬁcacy of
treatment.
3. Inhaler technique and diary cards, checked carefully to fol-
low up treatment compliance.
4. The occurrence of any adverse events.
5. Use and frequency of rescue medication (SABA).
Study design
Patients’ education was considered as an integral part of the
study. Disease etiology, risk factors and treatment instructions
were explained to each patient including lifestyle modiﬁca-
tions. All groups were shared to some extent the same hygiene,
treatment instructions and recommendations that deal with
lifestyle changes to complete treatment and prevent recurrence.
Once patients were seen and examined, the data were
logged onto the case report form (CRF), which was designed
to keep complete and accurate patient’s medical records.
CRF was recorded at each visit, it monitors and examines pa-
tients’ general feedbacks, patient compliance, night awareness,
general health status (shorten of breath, chest pain, difﬁculty
talking, blue lips or ﬁngernails), persistent wheezing or cough,
feeling anxiety or panic and any side effects (mouth candidia-
sis, dysphonia, skin fragility, . . ., etc.).
In a random manner, Patients were grouped into either re-
ceive treatment once daily with inhaled ﬂuticasone propionate
(Flixotide MDI, GlaxoWellcome, Egypt), or oral mentulokast
10 mg (Singlular, Merck Sharp, Egypt) for 16 weeks. mentu-
lokast treated patients were asked to take the drug on empty
stomach (either 1 h before meal or 2 h after meals) because
the bioavailability of mentulokast is reduced by food [7],
Throughout the study, patients used salbutamol when needed
in respect to the breakthrough in asthma symptoms. Patients
who had to use either oral or injection corticosteroids were dis-
qualiﬁed from the study. Fig. 1 describes the basic design of
the study.
Procedures
At the ﬁrst clinic visit, all subjects were subjected to full clinical
history according to a pre-designed sheet. At each clinic visit
(0, 2, 4, 6, 8, and 12 weeks post treatment) Pulmonary func-
tions were assessed using spirometer, adverse effects and the
use of other medications were investigated and follow up
sheets were updated.
At weeks 1 and 16 visits on, all patients were subjected to
clinical examination, routine inspection (plain chest X-ray,
Pulmonary function test and FENO) and speciﬁc biomarkers
(complete blood count [CBC], IgE, eosinophil counts and
IL-4).
Figure 1 Schematic of study design.
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Data are presented as means and SD values. One-way ANO-
VA was used to study the interaction between the three groups
before and after treatment for the different variables investi-
gated. Tukey post hoc test has been considered for pair-wise
comparison among the means when ANOVA test was
signiﬁcant.
The signiﬁcance level was set at p 6 0.05. Statistical analysis
was performed with IBM SPSS (SPSS Inc., IBM Corpora-
tion, NY, USA) statistics version 20 for Windows.
Results
Asthmatic patients had signiﬁcant lower levels of all spiromet-
ric function tests, and signiﬁcant higher levels of FENO, IgE
and eosinophil count when compared to controls. After the
treatment period of 16 weeks, the two groups of asthmatic pa-
tients had signiﬁcant improvement of all spirometric function
tests and signiﬁcant reduction in FENO, IgE levels and eosin-
ophil count. The levels of IgE, and eosinophilic count percent-
age were signiﬁcantly lower in asthmatic patients who were
treated with ﬂuticasone propionate when compared with those
treated with montelukast as shown in Tables 1 and 2.
Additionally improvements were observed with percentage
of symptom-free days, the frequency of sleep disturbance over
night because of asthma, the unnecessity of short beta agonists
and percentage of fully relieved days. After treatment therewas a signiﬁcant positive correlation between FENO level
and eosinophil count (r= 0.272, p= 0.047); the FENO was
negatively correlated with FEV1 count (r= 0.263, p= 0.01);
eosinophil count was negatively correlated with FEV1 count
(r= 0.179, p= 0.01) and FENO was negatively correlated
with PEFR count (r= 0.221, p= 0.01) as shown in Figs. 2–5.Discussion
Leukotriene antagonists were compared in several studies with
other asthma therapies [8]. It was also compared to the use of
ICS in the persistent asthma, in this context systematic reviews
concluded that persistent asthmatic patients are more suscepti-
ble by 65% to asthma exacerbation that results in use of sys-
tematic corticosteroids than those treated by the ICS [9,10].
These reviews were considering adults and children asthmatic
patients and it revealed that leukotriene modiﬁers as an add-
on therapy to ICS do not show signiﬁcant decrease in the
use of systematic corticosteroids [9,10].
In comparing Leukotriene modiﬁers and placebo in a com-
parative study with randomization and double-blind charac-
teristics and it showed that they have a signiﬁcant effect on
asthma but did not compare the montelukast to ICs [11].
A few controlled studies are available comparing the long-
term (>4-week) efﬁcacy of a leukotriene receptor antagonist
with ICS in asthmatic patients [12–15] Similar results of those
studies were in agreement with this study that support the use
of the ICs in the mild persistent asthma.
Table 1 Pulmonary functions.
Variable Sig.
Control Mentulokast Fluticasone propionate
Mean (SD) Mean (SD) Mean (SD)
FVC Before treatment 94.8 (2.08)a 68.95 (2.44)b 71.18 (4.35)b <0.001***
After treatment 94.8 (2.08)a 73.86 (3.6)b 79.91 (5.53)b <0.001***
FEV1 Before treatment 87.7 (5.05)a 45.50 (5.66)b 46.85 (3.48)b <0.001***
After treatment 87.7 (5.05)a 51.49 (8.53)b 56.45 (5.19)b <0.001***
FEV1/FVC Before treatment 90.57 (6.36)a 65.92 (6.88)b 65.92 (4.77)b <0.001***
After treatment 90.57 (6.36)a 69.53 (10.08)b 70.68 (4.97)b <0.001***
PEFR Before treatment 81.90 (5.64)a 60.80 (8.79)b 60.75 (8.2)b <0.001***
After treatment 81.90 (5.64)a 67.02 (9.89)b 73.31 (9.36)b <0.001***
Means with the same letter within each row are not signiﬁcantly different at p=0.05.
*** = Signiﬁcant.
Table 2 Biomarkers and FENO.
Variable Sig.
Control Mentulokast Fluticasone propionate
Mean (SD) Mean (SD) Mean (SD)
IgE Before treatment 447.95 (405.43)a 421.45 (350.83)a 479.45 (388.56)a 0.891 NS
After treatment 447.95 (405.43)a 329.96 (266.9)a 243.78 (196.11)a 0.110 NS
Eosinophil % Before treatment 2.60 (1.54)a 9.63 (3.06)b 9.05 (2.5)b <0.001***
After treatment 2.60 (1.54)a 6.43 (1.83)c 4.45 (1.13)b <0.001***
IL-4 Before treatment 50.07 (100.03)a 382.59 (894.63)a 148.52 (449.94)a 0.121 NS
After treatment 50.07 (100.03)a 342.81 (870.87)a 131.75 (451.98)a 0.169 NS
Nitric oxide Before treatment 26.40 (1.64)a 40.55 (3.58)b 36.85 (8.44)b <0.001***
After treatment 26.40 (1.64)a 33.83 (3.0)c 29.85 (6.86)b <0.001***
Means with the same letter within each row are not signiﬁcantly different at p=0.05.
*** = Signiﬁcant.
Figure 2 The correlation of levels of eosinophil % and nitric oxide in asthmatic patients.
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Figure 3 The correlation of levels of FEV1 and nitric oxide in asthmatic patients.
Figure 4 The correlation of levels of FEV1 and eosinophil % in asthmatic patients.
Cs vs. LMs for mild persistent asthma 367Another randomized study revealed the signiﬁcant
improvements with regard to Spirometer measurements and
asthma symptoms in a 3 month period of treatment with ICS
compared with LTRA in a similar patient population. The
greater improvement was assessed by spirometer measure-
ments (FEV1 and PEFR), asthma symptom control and the
unneeded short acting beta agonist use. Moreover it showedthat ICS is four times more effective than LTRA. Both treat-
ments were well tolerated [12].
Another study focusing on mild to moderate persistent
asthma showed the controlling effectiveness of ICS and differ-
ent advantages of ICS over LTRA. Furthermore, it showed
that ICS signiﬁcantly improved the pulmonary functions at
the initial, mid and ﬁnal phases of treatment. It showed also
Figure 5 The correlation of levels of PEFR and nitric oxide in asthmatic patient.
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signiﬁcant difference in terms of adverse effects between the
two groups was observed [14].
Some clinical studies showed different results than the re-
sults presented in this study, like the randomized and single
blinded study that demonstrated the insigniﬁcant difference
of ICS and LTRA in the initial improvements of the bronchial
constrictions [16].
Also another 2 month double blind study that was investi-
gating brachial biopsies has demonstrated non-signiﬁcant dif-
ference between ﬂuticasone propionate based treatment and
mentulokast-based treatment. Both ICS and LTRA were insig-
niﬁcantly different in decreasing eosinophilia count, however
ICS was more signiﬁcant in controlling mast cells [17].
However, several authors reported improvement in pul-
monary function tests in asthmatic patients following ICS
therapy compared to leukotriene modiﬁer [13,18].
The results from the present study revealed that the use of
ﬂuticasone propinate of 200 lg as ﬁrst-line therapy has higher
effectiveness than montelukast 10 mg in controlling asthma
over a period of 16 weeks. This was demonstrated by the high-
er improvements in the (FEV1) and (PEFR) in terms of per-
centage of change. Additionally improvements were in the
percentage of symptom-free days, the unneeded short acting
beta agonist and the frequency of sleep disturbance over night
because of asthma.
Conclusions
The ﬁrst-line therapy using ﬂuticasone propinate with a dose
of 200 lg was of higher clinical effectiveness over montelukast
(10 mg) in the overall asthma control during a treatment dura-
tion of 16-week treatment period. That supports currentGINA asthma treatment guidelines that perceive ICS as the
best long-term controller in controlling persistent asthma.References
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